<DOC>
	<DOCNO>NCT02612246</DOCNO>
	<brief_summary>The purpose First-in-Human study evaluate safety tolerability single ascend oral dos GLPG1972 give healthy subject , compare placebo . Also , safety tolerability multiple ascend oral dos GLPG1972 give healthy subject daily 14 day compare placebo , evaluate . Furthermore , course study single multiple oral dose administration , amount GLPG1972 present blood urine ( pharmacokinetics ) characterize . The effect food pharmacokinetics GLPG1972 also evaluate . The potential cytochrome P450 ( CYP ) 3A4 interaction repeat dose GLPG1972 explore well . During course study multiple oral dose administration , effect GLPG1972 biomarkers present blood ( pharmacodynamics ) characterize .</brief_summary>
	<brief_title>First-in-Human Single Multiple Dose GLPG1972</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Males 1850 year age Subjects must body mass index 1830 kg/mÂ² Subjects must judge good health base upon result medical history , physical examination , vital sign , 12lead electrocardiogram laboratory profile A subject know hypersensitivity study drug ingredient significant allergic reaction drug Concurrent participation participation within 8 week prior initial study drug administration drug/device investigational research study A subject active drug alcohol abuse within 2 year prior initial study drug administration Current sexually active ( and/or child wish ) male ; contraception method use</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>